Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Deferred Taxes (2023 - 2025)

Historic Deferred Taxes for Protalix BioTherapeutics (PLX) over the last 3 years, with Q3 2025 value amounting to $59000.0.

  • Protalix BioTherapeutics' Deferred Taxes fell 8668.17% to $59000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $177000.0, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of $236000.0 for FY2024, which is 10763.26% up from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Deferred Taxes is $59000.0, which was down 8668.17% from $231000.0 recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Deferred Taxes registered a high of $443000.0 during Q3 2024, and its lowest value of -$3.1 million during Q2 2023.
  • Over the past 3 years, Protalix BioTherapeutics' median Deferred Taxes value was -$15500.0 (recorded in 2023), while the average stood at -$334875.0.
  • In the last 5 years, Protalix BioTherapeutics' Deferred Taxes soared by 106578.95% in 2024 and then plummeted by 8668.17% in 2025.
  • Quarter analysis of 3 years shows Protalix BioTherapeutics' Deferred Taxes stood at $38000.0 in 2023, then surged by 1065.79% to $443000.0 in 2024, then tumbled by 86.68% to $59000.0 in 2025.
  • Its last three reported values are $59000.0 in Q3 2025, $231000.0 for Q2 2025, and -$113000.0 during Q1 2025.